For Wednesday, January 25th
ATTD, COWI, BLRX, CBAI, EGOC, PPJE
Our Stocks to Watch tomorrow include Attitude Drinks Inc. (OTCBB: ATTD), CoroWare Inc. (OTC: COWI), BioLineRx Ltd. (NASDAQ: BLRX), Cord Blood America Inc. (OTCBB: CBAI), Energy 1 Corp. (OTC: EGOC) and PPJ Enterprise (OTC: PPJE).
ATTITUDE DRINKS INCORPORATED (OTCBB: ATTD)
"Up 125.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/ATTD.php
Attitude Drinks Inc. is an innovative, beverage brand development company with a focus on functional milk, ready-to-drink beverages. Phase III® Recovery Drink is the company's first, functional milk drink exploiting recent scientific evidence of the benefits of milk and protein as an exercise recovery aid. The February 2010 launch of Phase III marks the first time a sports drink has been formulated from real milk.
ATTD News:
January 24 - Attitude Drinks Announces Authorization in Walgreens Stores Within State of Florida
Attitude Drinks (OTCBB: ATTD), an innovative brand beverage development company and creator of the Phase III® Recovery brand, today announced a sales agreement with Walgreens, of Deerfield, IL.
The brand will be distributed to Walgreens stores throughout the majority of the state. This represents over 800 stores within the chain. Walgreens, a company built around the concept of one stop shopping, has now increased their focus into the health & wellness arena. They are striving to become the first choice for "health & daily living" in promoting what they refer to as a "well experience."
Roy Warren, CEO of Attitude Drinks commented, "The introduction of Phase III® into the authorized Walgreens locations throughout the state of Florida is a great indicator of brand growth and reception within the beverage community. The selling of Phase III® into these Walgreens stores, a chain recognized as one of the strongest drug and convenience stores in the country, is exciting and flattering. We intend to support this fantastic new relationship in raising the sales to their fullest potential."
"We are excited about the authorization of Phase III® Recovery in the Florida Division of Walgreens. It is clear that Florida consumers are looking to purchase Phase III® and now that it is available in Walgreens--problem solved," commented Jack Shea, Executive Vice President of Sales for Attitude.
COROWARE INCORPORATED (OTCBB: COWI)
"Up 100.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/COWI.php
Headquartered in Redmond, Washington, CoroWare is a solutions integrator with expertise in mobile robotics, personal telepresence, IT consulting and software development.
COWI News:
January 10 - Coroware Announces CoroBot Upgrades and Options
New Hardware Options and Software Upgrades Facilitate More Powerful Applications
CoroWare, Inc. (OTC: COWI) announced new software upgrades and hardware options for the CoroBot® Classic and CoroBot Explorer product lines. These new capabilities give researchers, educators and engineers the ability to rapidly develop more powerful autonomous unmanned ground vehicle (UGV) applications.
The software upgrades include full Robotic Operating System (ROS) compatibility and an improved teleoperation application. ROS is an open source framework for creating robotic applications, and is rapidly becoming an industry standard. All of CoroWare's mobile robots are designed to be fully ROS compatible. Out of the box, the CoroBot product line features a teleoperation application that allows users to remotely pilot the robot and view output from the cameras and sensors, whether over a private network or over the Internet.
"Our customers are looking for platforms that take advantage of open platforms such as ROS," said Andrew Zager , robotics product marketing engineer at CoroWare. "In addition to the applications developed by CoroWare, researchers and educators have access to a extensive catalog of open source robotic applications such as mapping, image recognition and navigation."
CoroWare is also offering new hardware options to enhance the abilities of the CoroBot product line. Customers can now add a Microsoft Kinect® to any CoroBot either pre-installed with ROS or upgraded to support ROS. Microsoft Kinect gives users infrared imaging and depth perception to create real-time three dimensional maps. In addition, the stock CoroBot camera has been upgraded to support 1080p full HD video quality.
With the needs of field researchers in mind, CoroWare is also offering customers the option of ordering Lithium Ferrous Phosphate (LiFePO4) batteries. These higher performance batteries offer higher power density and faster charge rates than typical unmanned vehicle batteries.
These new CoroBot product line upgrades and options are available today. The CoroBot product line includes a one year factory warranty at no additional charge. Customers have the option of purchasing extended warranty and premium support plans. Customers should contact a CoroWare account representative or authorized reseller for corporate and educational pricing details.
BIOLINERX LIMITED (NASDAQ: BLRX)
"Up 68.69% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/BLRX.php
BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, is currently undergoing a pivotal CE-Mark registration trial and has been out-licensed to Ikaria Inc. for a total deal value of $282.5 million, in addition to sales royalties; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development and BL-7040 for treating Inflammatory Bowel Disease (IBD) has completed Phase I. In addition, BioLineRx has 12 products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.
BLRX News:
January 24 - BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C
BioLineRx (NASDAQ: BLRX), a biopharmaceutical development company, announced that it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C.
BL-8020 has been developed for anti-viral therapy by Professor Philippe Halfon, Co-Founder and President of Genoscience. Prof. Halfon is a founder of several biotechnology companies and is world renowned for his work on HIV (AIDS virus), HPV (human papilloma virus causing cervical cancer) and Hepatitis.
BL-8020 acts via a unique mechanism of action, by inhibiting Hepatitis C virus (HCV)-induced autophagy, which differs from the mechanism of currently used anti-HCV agents. BL-8020's safety and efficacy were demonstrated in pre-clinical studies. These studies have shown that BL-8020, when combined with other anti-Hepatitis C virus (HCV) agents, has a synergistic effect. BL-8020's synergistic effect on other therapies is likely to increase their potency and reduce the numerous adverse effects often associated with these drugs, by enabling utilization of lower dosages. In addition BL-8020 may reduce therapy duration, which is currently up to 48 weeks. The use of two drugs acting by different mechanisms is also likely to be beneficial for patients who have developed resistance to current treatments and is an effective strategy used against other viruses such as HIV.
Dr. Kinneret Savitsky, CEO of BioLineRx, said, “We are excited about entering the field of Hepatitis C therapeutics, which is a very important field in the pharmaceutical market today. The current global Hepatitis market is estimated at approximately $6.5 billion and is growing steadily. Current therapies are characterized by numerous severe side effects, long treatment duration and development of resistance. In these respects, BL-8020 has a demonstrated safety and efficacy profile, may shorten therapy duration and may combat resistance by acting as an add-on platform which can potentially be combined with other oral Hepatitis C therapies to increase their efficacy.”
"We were impressed by the drug development expertise of the BioLineRx team and are very pleased to collaborate with them for the further development of our product for the treatment of Hepatitis C," said Prof. Philippe Halfon, Co-Founder and President of Genoscience. "There is clearly a huge unmet medical need in finding a safe and effective treatment for the disease, and based on pre-clinical results, its unique mechanism of action and synergistic effect, we believe that our product, especially when combined with other available Hepatitis C drugs, has the potential to bring remedy to millions worldwide."
ABOUT HEPATITIS C
Hepatitis C infection is a blood borne infection of the liver caused by the Hepatitis C virus (HCV) which becomes chronic in about 85% of cases. According to the World Health Organization (WHO), more than 170 million people worldwide are chronically infected with HCV. In addition, HCV infection is the leading cause of liver transplantation and is a risk factor for liver cancer. The global Hepatitis market was estimated at $6.5 billion in 2010 and is forecasted to grow to $11.5 billion in 2016.
CORD BLOOD AMERICA INCORPORATED (OTCBB: CBAI)
"Up 21.15% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/CBAI.php
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
CBAI News:
January 24 - Breakthrough Therapy Using Cord Blood Banking Driving Stem Cell Industry
Five Star Equities Provides Stock Research on Cord Blood America & Aastrom Biosciences
Given some positive trends, the stem cell market could be set to skyrocket this year. A recent report from Kalorama Information titled "Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development," estimates that the market for stem cell technologies will rise to over $700 million this year and could reach over $1 billion. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Cord Blood America Inc. (OTCBB: CBAI) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Access to the full company reports can be found at:
www.fivestarequities.com/CBAI
www.fivestarequities.com/ASTM
Kalorama finds that cell therapies are largely confined to a few conditions. Oncological conditions such as leukemia, multiple myeloma and non-Hodgkins lymphoma are some of the most popular areas of research, although certain non-cancerous diseases like aplastic anemia, immunodeficiency and lupus are also increasingly addressed with stem cells.
Kalorama finds that cord blood banking is a source of revenue growth in the stem cell market. U.S. researchers are currently undergoing a phase I safety study using a child's umbilical cord blood stem cells to try to restore hearing loss. "This study is exciting because it might offer a non-surgical option for some children with profound hearing loss," explains Dr. James Baumgartner, sponsor of the study and guest research collaborator at The University of Texas Health Science Center at Houston Medical School.
Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.
Stem cells from umbilical cords do not pose an ethical dilemma because the cells come from a source that would otherwise be discarded, Science Daily reports. Recent studies suggest that stem cells from umbilical cords have been converted into other types of cells, which may eventually lead to new treatment options for nervous system diseases. "This is the first time this has been done with non-embryonic stem cells," says James Hickman, a University of Central Florida bioengineer and leader of the research group.
ENERGY 1 CORPORATION (OTC: EGOC)
"Up 20.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/EGOC.php
Energy 1 Corporation is a U.S.-based Energy Research and Development Corporation, which is developing energy and emission solutions for the post carbon economy for the transportation industry.
EGOC News:
January 24 - Energy 1 Corporation Provides Status Update on Mid-East Project
Energy 1 Corporation (OTC: EGOC) announces that product engineering for integration on the Mercedes 0-457 diesel powered transit bus is near complete and anticipates Phase II of – in use – product demonstration & end-user testing to begin within 4 to 6 weeks from today.
"Phase II is the final phase of this demonstration & end-user testing protocol for product readiness within the middle-east market," said Raymond T. Brown, Chairman of E1. "We are on schedule and on target. With this last hurdle behind us, we'll be ready to start manufacturing pre-configured units for resale into the retrofit market for emission reduction on transit buses within the region; and while increased fuel efficiencies may not be as critical to customers in this area of the world verses Europe, the US & the Asian-Pacific markets, the fact that we include it answers any additional ROI calculations the consumer might have as part of their buying decision."
PPJ ENTERPRISE (OTC: PPJE)
"Up 61.67% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/PPJE.php
PPJ Enterprise is a leading provider of comprehensive, full-service medical practice management software. The company believes its proprietary Software System is the only fully automated medical billing and practice management system in the U.S. today.
PPJE News:
January 6 - PPJ Enterprise Revenue Projections for 2012
PPJ Enterprise (OTC: PPJE), a proprietary automated health care software company, shared with the public the estimated 2012 revenue projections for the company's business activities.
Based on the current company presence on the U.S. health care market, namely the current contracts and contract negotiations, the management of the Nevada based PPJ Enterprise estimates the projected revenues to reach between $1.5 to $2 million in 2012. This sum will include revenues from all the products offered by the PPJ Enterprise: pharmacy billing, pain management billing and workers comp. collection accounts.
Company CEO, Chandana Basu stated, "The U.S. Health Care Spending reached $2.5 trillion in 2010. We are actively focusing our sales activities, and we expect to fully capitalize from being located to the proximity to important U.S. markets such as California , which is one of largest markets for automated billing systems in the U.S.
"PPJ Enterprise is profitable and self-sufficient and we intent to grow organically on the health care market and continue to seek new business opportunities that may present themselves in the currently shifting U.S. health care, and we expect to continue to update and grow the sales of our proprietary systems, namely reimbursement cycle software, online health information digital systems software, and practice information management digital system software for health care providers and general businesses.
"As we have stated previously, these are exciting times for PPJ Enterprise. We have many solid business developments in the wings and we intend to update our investor base as these developments unfold."
|
